about
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsCritically short telomeres and toxicity of chemotherapy in early breast cancerProspective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.Selection of extreme phenotypes: the role of clinical observation in translational research.Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/AktCCR5 expression influences the progression of human breast cancer in a p53-dependent mannerDermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring Pneumonectomy.In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.Current controversies in the management of early breast cancer.Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.Advanced breast cancer clinical nursing curriculum: review and recommendations.Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.Targeting cytoskeleton reorganisation as antimetastatic treatment.Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.Strategies to design clinical studies to identify predictive biomarkers in cancer research.Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors.Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trialNew synthetic inhibitors of fatty acid synthase with anticancer activity.Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer.Cancer care in rural areas.Management of metastatic breast cancer: are we prepared to cope with our own success?Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters.Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
P50
Q24561962-4878B5EB-D329-401A-A711-1F2100B28A70Q33591567-B1B2843A-AF2D-4600-8B6F-C6E9E2286B91Q34190743-AA84CF43-2642-4BDE-8069-ECF75539E652Q34384968-EC11CBFB-6592-4014-9C6B-FE04BBCFBAC2Q35678397-AE4FCA76-2638-4D62-B663-8CB0565BDB4FQ35889665-3384E1A0-6C26-444B-9576-F3B17B4284A0Q35945055-B43C7834-BB6C-432D-8EB6-68462C0B2985Q36371823-253E110F-3E1A-48E7-943C-A62EA0BF0D52Q36438216-9B381619-2A37-40AD-B7EB-1BF42B976852Q36747337-7E191917-223C-43A5-8435-D8DB02351FADQ36862139-41313FB0-9F6E-459F-BEFD-D587C17D6700Q36875147-4CC8512F-BADE-42BC-B4CE-0525BE510A06Q37588649-1B871DEF-E07D-479F-A256-E0A4EE71BD29Q37706959-BFD88D38-9588-4B07-AD75-A00A5FE4FB46Q37800284-EA0DC443-1D2C-4CE7-9FF8-5D54283B95F8Q38393636-55E4E6D6-31F0-4307-82D4-4BB901580D40Q38693863-A8E3AA2E-921B-48FF-9453-27F7F253B32FQ38770451-8EED4D63-A19F-4839-961D-0F04E8BBD4DEQ38823761-E907D14C-ADF2-4A11-8D3B-E98F5ECC954FQ38949147-AEABEEE2-F505-454D-8D08-F1AF0F848CD4Q38967971-35622C03-2496-4B6F-B095-960337E0C7D1Q39353593-C1CAD942-8B61-4E5A-A078-A132F2993CD7Q40011785-829B1043-E7B2-4391-AFD7-EA8948CDAA91Q40022130-B6DFA2EB-EC71-43A5-8208-253C34491CA6Q40132633-EE6ACF4D-1961-46DE-A11A-95678FBDE757Q40155442-2CFE89C9-CC00-46B5-BA8F-2A2F90FB0F01Q40355597-0FD49223-44F6-4CC2-A7EE-128BEEB6ED42Q40560922-BC2ECFD5-2B5C-42CA-9625-41A680FB91D6Q42848545-95BAEAAF-3D92-4890-965F-ACE53310B7CFQ43248891-75AE8E2D-E191-4B5E-852D-763E8B1DFBD6Q43248919-9CCB4956-BDE2-47C2-AB9F-B32EEE49F86BQ44754071-431DA31F-2395-4C8E-BB13-096FDD801572Q45193153-2A09D0D5-0B5B-4693-A361-840ADC21FA61Q46497887-72DC45A3-8179-44DC-8833-A0A4005DDDBCQ46798803-A9B194AA-2196-4BA5-8CAE-CF854D895BA2Q46958362-9ABB42D4-BE2B-4786-9B42-6F08C5C98089Q46976847-13E5AC06-F406-4BB5-BDFF-B598122C87ACQ47877504-5951488E-E36A-4640-B47B-3281BB8C235BQ48145064-ED737FC7-CED2-405A-A2E6-E67BD53B9A36Q48243603-978F1292-A1DF-456D-8761-45EEE7CD460D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ramon Colomer
@ast
Ramon Colomer
@en
Ramon Colomer
@es
Ramon Colomer
@nl
Ramon Colomer
@sl
type
label
Ramon Colomer
@ast
Ramon Colomer
@en
Ramon Colomer
@es
Ramon Colomer
@nl
Ramon Colomer
@sl
prefLabel
Ramon Colomer
@ast
Ramon Colomer
@en
Ramon Colomer
@es
Ramon Colomer
@nl
Ramon Colomer
@sl
P1053
C-5142-2008
P106
P21
P31
P3829
P496
0000-0002-6393-3444
P569
2000-01-01T00:00:00Z